Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery

DISEASE CHARACTERISTICS:

Histologically confirmed stage II or IIIA non-small cell lung cancer

T1-3, N1-2, M0
No stage IIIB (e.g., contralateral N3), stage IV (M1), or T3, N0, M0 disease
N1 disease eligible only if hilar lymph node involvement present
No bronchoalveolar carcinoma with lobar or multilobar involvement
No small cell lung carcinoma, including mixed histology

No more than 7 weeks since prior surgery (lobectomy, sleeve resection, bilobectomy, or pneumonectomy)

Negative surgical margins
No incompletely resected gross disease OR
No microscopically positive bronchial or vascular margins
No known CNS metastasis

PATIENT CHARACTERISTICS:

Age:

18 and over

Performance status:

Zubrod 0-1

Life expectancy:

Not specified

Hematopoietic:

Absolute neutrophil count at least 2,000/mm^3
Platelet count at least 100,000/mm^3

Hepatic:

Not specified

Renal:

Creatinine no greater than 1.5 mg/dL OR
Creatinine clearance greater than 60 mL/min

Cardiovascular:

No superior vena cava syndrome

Pulmonary:

FEV_1 at least 1.0 L

Gastrointestinal:

No prior celiac disease, familial polyposis, Turcot's syndrome, Gardner's syndrome, Peutz-Jegher's syndrome, or hereditary non-polyposis colon cancer
No prior colitis, inflammatory bowel disease, or pancreatitis within the past 10 years

Other:

Not pregnant
Negative pregnancy test
Fertile patients must use effective contraception
No known sensitivity to rodent proteins
No prior hypersensitivity or contraindication to study treatments (e.g., monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, aluminum hydroxide, or murine proteins) or any excipients
No prior clinically significant hypersensitivity reactions (e.g., angioedema, anaphylaxis, or serious dermatological manifestations) or asthmatic attacks requiring hospitalization
No prior immune or immunodeficiency disorders (e.g., HIV, sarcoidosis, tuberculosis, rheumatoid arthritis, or autoimmune disorders)
No prior seizure disorder requiring continuous medication
No active infection
No other prior or concurrent malignancy within the past 3 years except surgically treated carcinoma in situ of the cervix or squamous cell or basal cell skin cancer
No medical contraindication to surgery, radiotherapy, or immunotherapy
No prior drug or alcohol abuse (excluding nicotine) within the past 12 months
No prior psychiatric or addictive disorder that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy:

No prior murine antibodies (e.g., OncoScint scan)
No prior monoclonal antibody 11D10 anti-idiotype vaccine, monoclonal antibody 3H1 anti-idiotype vaccine, or other investigational carcinoembryonic antigen-derived therapy
At least 3 years since other prior immunotherapy
At least 30 days since prior immunization (e.g., influenza)
No immunomodulatory therapy (e.g., gold, auranofin, hydroxychloroquine, sulfasalazine, penicillamine, levamisole, dapsone, azathioprine, intravenous immunoglobulin, leukotriene antagonists, cromoglycate, ketotifen, nedocromil, psoralin-ultraviolet-light, or plasmapheresis) within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer

Chemotherapy:

At least 3 years since prior chemotherapy except topical therapy
No concurrent methotrexate or cyclophosphamide

Endocrine therapy:

At least 45 days since prior corticosteroids
No concurrent systemic corticosteroids

Radiotherapy:

No prior thoracic radiotherapy

Surgery:

See Disease Characteristics

Other:

At least 45 days since prior immunosuppressants
No investigational agents within 30 prior to the first dose of study drug or 5 half-lives of the action of the agent, whichever is longer
No concurrent amifostine
No concurrent cyclosporine
No other concurrent immunosuppressants
No concurrent chronic systemic antihistamines